Viridian Therapeutics Inc (NASDAQ: VRDN) kicked off on Tuesday, down -1.76% from the previous trading day, before settling in for the closing price of $21.56. Over the past 52 weeks, VRDN has traded in a range of $10.93-$24.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -12.71% over the last five years. While this was happening, its average annual earnings per share was recorded 27.08%. With a float of $55.56 million, this company’s outstanding shares have now reached $63.89 million.
The firm has a total of 96 workers. Let’s measure their productivity. In terms of profitability, gross margin is -257.64%, operating margin of -87078.47%, and the pretax margin is -79185.76%.
Viridian Therapeutics Inc (VRDN) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc is 13.04%, while institutional ownership is 96.03%. The most recent insider transaction that took place on Sep 13 ’24, was worth 30,000,000. In this transaction Director of this company bought 1,600,000 shares at a rate of $18.75, taking the stock ownership to the 3,445,813 shares. Before that another transaction happened on Jan 22 ’24, when Company’s Director bought 476,190 for $21.00, making the entire transaction worth $9,999,990. This insider now owns 1,839,954 shares in total.
Viridian Therapeutics Inc (VRDN) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -1.09 earnings per share (EPS), higher than consensus estimate (set at -1.27) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.08% per share during the next fiscal year.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Take a look at Viridian Therapeutics Inc’s (VRDN) current performance indicators. Last quarter, stock had a quick ratio of 23.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4666.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.25, a number that is poised to hit -1.06 in the next quarter and is forecasted to reach -4.18 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Analysing the last 5-days average volume posted by the [Viridian Therapeutics Inc, VRDN], we can find that recorded value of 3.46 million was better than the volume posted last year of 1.12 million. As of the previous 9 days, the stock’s Stochastic %D was 83.59%. Additionally, its Average True Range was 1.55.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 78.87%, which indicates a significant increase from 75.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 127.56% in the past 14 days, which was higher than the 73.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.71, while its 200-day Moving Average is $16.57. Now, the first resistance to watch is $21.94. This is followed by the second major resistance level at $22.70. The third major resistance level sits at $23.35. If the price goes on to break the first support level at $20.53, it is likely to go to the next support level at $19.88. Should the price break the second support level, the third support level stands at $19.12.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
The company with the Market Capitalisation of 1.35 billion has total of 63,822K Shares Outstanding. Its annual sales at the moment are 310 K in contrast with the sum of -237,730 K annual income. Company’s last quarter sales were recorded 70 K and last quarter income was -64,990 K.
